Our Resources | Association for Accessible Medicines

COVID-19 and AAM - FAQ's and resources from the U.S. generics and biosimilars industry.

Feb 20, 2020 | Rachel Schwartz

Insurers Fail to Get New Generics to America’s Patients

2020 Avalere Analysis Generic Tiers

Feb 13, 2020 | Rachel Schwartz

Avalere Analysis Finds Medicare Part D Patients Are Paying More For Their Lower-Cost Generics

Feb 10, 2020 | Rachel Schwartz

AAM Statement on Resignation of Chip Davis

Feb 6, 2020 | Rachel Schwartz

AAM Announces 2020 Associate Members

Feb 6, 2020 | Rachel Schwartz

AAM Announces 2020 Board of Directors

Feb 5, 2020 | Rachel Schwartz

The Association for Accessible Medicines Wins Public Affairs Council’s Innovations in Public Affairs Award

Jan 29, 2020 | Rachel Schwartz

AAM Statement on Signing USMCA into Law

Jan 23, 2020 | Rachel Schwartz

AAM Statement on Avalere Analysis of Generic Substitution

Jan 23, 2020 | Craig Burton

White Paper: Sidelined: How Seniors Miss Out On Savings Available Through Generic Substitution

Jan 16, 2020 | Rachel Schwartz

AAM Statement on Senate Passage of USMCA Agreement

Jan 9, 2020 | Karin Hessler

Competition Matters. That’s Why We Need to Further Improve IPR.

Jan 9, 2020 | Erica Klinger

Give IPR the Green Light